Safety Information
| Description | Publish Date | LINKS |
|---|---|---|
| Important safety information on Dolutegravir in Jordan |
10/10/2018 |
 |
| Important safety information on Abacavir: Hypersensitivity reaction - educational slide deck | 15/02/2024 |
|
| Important safety information on Non-steroidal anti-inflammatory drugs (NSAlDs) in Jordan | 11/06/2021 | |
| Important safety information on Cephalosporins in Jordan (Safety Notification_Cephalosporins and risk of seizure) | 01/03/2023 | |
Important safety information on Cephalosporins in Jordan (Safety Notification_Cephalosporins and risk of neurotoxicity) |
07/03/2023 |
|
Important safety information on Amoxicillin / Amoxicillin and clavulanic acid containing products in Jordan |
09/09/2023 | |
| Important safety information on Cefuroxime sodium in Jordan (Safety Notification_Cefuroxime Class 4 Defect MHRA) | 30-10-2023 | |
| Important safety information on Paroxetine in Jordan (Safety Notification_EMA communication issued relating to Paroxetine label update) | 27-10-2023 | |
| Important safety information on Dolutegravir in Jordan (Safety Notification_Korean label update for Dolutegravir containing products) | 01-11-2023 | |
| Important safety information on Sumatriptan in Jordan (Safety Notification_Sumatriptan and breast pain) | 07-11-2023 | |
| Important safety information on Topical Corticosteroids containing products in Jordan | 15-11-2023 | |
| Important safety information on Hepatitis B surface antigen recombinant vaccine in Jordan (Initial Safety Notification Engerix-B and Myelitis_November 2023) | 17-11-2023 | |
| Important safety information on Hepatitis B surface antigen recombinant vaccine in Jordan (Updated Safety Notification Engerix-B and Myelitis_December 2023) | 02-01-2024 | |
Important safety information on Amoxicillin/clavulanic acid containing products - MedSafe communication regarding labelling updates |
18/12/2023 |
|
Important safety information on Zanamivir containing products - Precautions for prescribing and administering flu medications (zanamivir) |
26/12/2023 |
|
Important safety information on Paroxetine containing products - Modifications of the information of medicines authorized by national procedure that contain Paroxetine_NPCV |
03/01/2024 |
|
Important safety information on Acyclovir containing products - Safety Notification EMA-PRAC: The MAH has been requested to provide cumulative reviews of the below-mentioned issues in the next PBRER to be submitted for acyclovir |
02/01/2024 |
|
Important safety information on Levetiracetam containing products - FDA Warns of Rare but Serious Drug Reaction - Keppra |
03/01/2024 |
|
Important safety information on Hepatitis B surface antigen recombinant vaccine (Updated Safety Notification Engerix-B and Myelitis_January 2024) |
25/01/2024 |
|
Important safety information on Lamotrigine containing products - Latest Prescriber Update (vol 45:1 March 2024) received from Medsafe |
18/03/2024 |
|
Important safety information on Abacavir containing products - Regarding amendments to the instructions for medical use of medicines containing abacavir |
19/03/2024 |
|
Important safety information on Lamotrigine containing products - Safety Signal received from Swissmedic: Lamictal - Interaction with hormone replacement therapies (HRT) |
04/04/2024 |
|
Important safety information on Hepatitis B surface antigen recombinant vaccine - Updated Safety Notification Engerix-B and Myelitis_May 2024 |
07/05/2024 |
|
Important safety information on Amoxicillin / clavulanic acid - DHCPL: Drug-induced enterocolitis syndrome, interaction with methotrexate, May 2024 revision |
17/05/2024 |
|
